As of 2026 there are roughly a dozen FDA-approved GLP-1 and incretin products on the US market, built from six molecules: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and the newest, orforglipron. They split into diabetes drugs, weight-management drugs, and a few that do both. Here is the full roster.
What counts as a GLP-1 product?
A GLP-1 product is any approved medicine whose active ingredient activates the GLP-1 receptor to lower blood sugar, slow gastric emptying, and reduce appetite. The category now also includes incretin combinations such as tirzepatide, which adds GIP receptor activity, and fixed-dose insulin blends. We group all of them here because patients and prescribers treat them as one therapeutic family. For the mechanism behind the class, see our overview of GLP-1 receptor agonist drugs.
Which GLP-1 products are FDA-approved in 2026?
The table below lists every currently marketed, FDA-approved option, its molecule, maker, primary indication, and delivery form.
| Brand | Molecule | Maker | Primary indication | Form |
|---|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes; CV risk | Weekly injection |
| Wegovy (injection) | Semaglutide 2.4 mg | Novo Nordisk | Weight management; CV risk; MASH | Weekly injection |
| Wegovy (pill) | Oral semaglutide 25 mg | Novo Nordisk | Weight management; CV risk | Daily tablet |
| Rybelsus | Oral semaglutide | Novo Nordisk | Type 2 diabetes | Daily tablet |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes | Weekly injection |
| Zepbound | Tirzepatide | Eli Lilly | Weight management; OSA | Weekly injection |
| Trulicity | Dulaglutide | Eli Lilly | Type 2 diabetes | Weekly injection |
| Victoza | Liraglutide | Novo Nordisk (+ generics) | Type 2 diabetes | Daily injection |
| Saxenda | Liraglutide 3 mg | Novo Nordisk (+ generic) | Weight management | Daily injection |
| Foundayo | Orforglipron | Eli Lilly | Weight management | Daily tablet |
| Soliqua | Insulin glargine + lixisenatide | Sanofi | Type 2 diabetes | Daily injection |
| Xultophy | Insulin degludec + liraglutide | Novo Nordisk | Type 2 diabetes | Daily injection |
What are the semaglutide products?
Semaglutide is the most widely prescribed molecule in the class, sold in four distinct products. Ozempic is the weekly diabetes injection. Wegovy is the same molecule titrated to a higher 2.4 mg weight-management dose, which the FDA also cleared to reduce cardiovascular events and, in 2025, to treat MASH (metabolic dysfunction-associated steatohepatitis). Rybelsus is a daily oral tablet for diabetes. The newest entry is the Wegovy pill, an oral semaglutide 25 mg tablet the FDA approved in December 2025 for weight management, the first oral GLP-1 cleared for that use. See our Ozempic guide and Wegovy guide for dosing and access detail.
How the semaglutide products differ
Ozempic and Rybelsus target diabetes; both Wegovy forms target weight. The injectable Wegovy reaches a higher effective dose than the pill is dosed to, but OASIS 4 trial data put oral semaglutide 25 mg at roughly 16.6% mean weight loss, close to the injection.
What are the tirzepatide products?
Tirzepatide is a dual GIP/GLP-1 receptor agonist made by Eli Lilly and sold as two brands. Mounjaro is approved for type 2 diabetes. Zepbound is the same drug for chronic weight management, and in December 2024 it became the first FDA-approved medication for obstructive sleep apnea in adults with obesity. In the SURMOUNT-1 trial, tirzepatide produced up to 22.5% mean weight loss at 72 weeks, the highest of any approved single agent. Our Mounjaro guide and Zepbound guide cover both labels.
What are the older daily and weekly GLP-1 products?
Several first-generation options remain on the market.
Liraglutide (Victoza, Saxenda)
Liraglutide is a daily injection. Victoza treats type 2 diabetes; Saxenda is the 3 mg weight-management version. Both now face generic competition: the FDA approved a generic of Victoza in December 2024 and Teva launched a generic Saxenda in August 2025, the first generic GLP-1 indicated for weight loss. See our Saxenda guide.
Dulaglutide (Trulicity)
Trulicity is a once-weekly diabetes injection from Eli Lilly. It produces solid A1c reduction and modest weight loss, and remains popular for its simple, no-titration auto-injector that needs no dose calculation.
Exenatide (Byetta, Bydureon) — discontinued
The first GLP-1 ever approved, exenatide, has effectively left the market. AstraZeneca discontinued Byetta in 2024 and the long-acting Bydureon BCise has also been discontinued, displaced by more effective weekly options.
What is new in 2026?
The headline addition is Foundayo (orforglipron), which the FDA approved on April 1, 2026 for chronic weight management. It is the first oral, non-peptide (small-molecule) GLP-1 receptor agonist, meaning it can be manufactured as a conventional pill without the absorption limits of peptide tablets. Because it is small-molecule, it does not require refrigeration or injection, which positions it as a scalable oral option alongside the Wegovy pill.
What is approved versus still in the pipeline
Not every drug in the news is approved. Retatrutide, Eli Lilly's triple GIP/GLP-1/glucagon agonist, remains in Phase 3 trials and is not FDA-approved as of 2026; analysts project a possible 2028 launch. Combination candidates like CagriSema and survodutide are likewise investigational. Only the products in the roster table above can be legally prescribed today.
How do you choose among GLP-1 products?
Choice usually comes down to indication, route, and access. Diabetes patients are steered toward Ozempic, Mounjaro, Trulicity, Rybelsus, or Victoza. Weight-management patients are steered toward Zepbound, Wegovy (pen or pill), Saxenda, or Foundayo. Route matters too: weekly injections suit people who dislike daily dosing, while pills suit needle-averse patients. Insurance coverage and the arrival of generic liraglutide increasingly shape the final decision as much as efficacy does.
How are GLP-1 products priced in 2026?
List prices for the branded weight-loss and diabetes injections cluster around $1,000 to $1,350 per month before insurance, though almost no one pays the full sticker. Manufacturer savings cards, cash-pay programs, and pharmacy bundles routinely cut that figure sharply. Novo Nordisk and Eli Lilly both run self-pay vial channels for their flagship weight drugs, which price well below the pen list. The arrival of generic liraglutide has begun to pull the older end of the market down, and the small-molecule design of orforglipron is expected to ease supply and cost pressure over time. Coverage, not chemistry, is usually the deciding factor at the pharmacy counter.
Diabetes versus weight-management coverage
Insurers have historically covered the diabetes indications (Ozempic, Mounjaro, Trulicity) more readily than the weight-management ones (Wegovy, Zepbound, Saxenda, Foundayo), because obesity coverage mandates vary by plan and state. That gap is why two chemically identical products, Ozempic and Wegovy or Mounjaro and Zepbound, can have very different out-of-pocket costs depending on which label is prescribed.
Frequently Asked Questions
Which GLP-1 product causes the most weight loss?
Among approved single agents, tirzepatide (Zepbound) leads, with up to about 22.5% mean weight loss in SURMOUNT-1, ahead of injectable semaglutide (Wegovy) at roughly 15% in STEP 1. The investigational triple agonist retatrutide has shown higher figures in trials but is not yet approved.
Are there any generic GLP-1 products?
Yes. Generic liraglutide is now available for both type 2 diabetes (referencing Victoza, 2024) and weight loss (referencing Saxenda, 2025). The newer molecules, semaglutide and tirzepatide, remain on-patent and have no FDA-approved generics in 2026.
Is there an oral GLP-1 for weight loss?
Two: the Wegovy pill (oral semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 2026). Rybelsus is an oral semaglutide too, but it is approved for diabetes, not weight management.
Which company makes the most GLP-1 products?
Novo Nordisk and Eli Lilly dominate. Novo makes the semaglutide and liraglutide lines (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda, Xultophy); Lilly makes tirzepatide and orforglipron (Mounjaro, Zepbound, Trulicity, Foundayo).
This article is for general information and is not medical advice. Discuss which product, if any, fits your situation with a licensed clinician.
